Oramed Pharmaceuticals Inc.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Oramed Pharmaceuticals is in Stage 2, the uptrend phase, now in week 10 (since Aug 17, 2026). It closed at $4.12, 22.8% below its 52-week high and above its 200-day average, which is rising.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. More about the company

$4.12

+0.73% today

$171M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ORMP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 14w

S4 17w

S2 43w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 20w → S1 10w → S2 5w → S3 3w → S4 9w → S1 10w → S4 13w → S1 6w → S4 14w → S1 1w → S4 17w → S1 3w → S2 43w → S3 2w → S2 10w current

Total tracked: 164 weeks across 15 stage runs.

ORMP among Biotechnology48th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…48	ORMPOramed Pharmaceuticals Inc.	Stage 2 · wk 10	94	−12.7%

vs 52W High

-22.8%

$2.04 lo$5.34 hi

22.8% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 10

1w13w26w

Week 10, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

2.9%

200 DMA: $4.00 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.51x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-12.7%

+2.2%

+7.3%

YTD

+51.9%

+88.9%

Scan Membership

Breakout Watch

Latest: 2024-03-18

4 appearances in last 60 days. First seen: 2019-12-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 10 · Vol 0.51x

2026-10-21S2

Wk 10 · Vol 0.37x

2026-10-20S2

Wk 10 · Vol 0.73x

2026-10-19S2

Wk 9 · Vol 0.84x

2026-10-16S2

Wk 9 · Vol 1.44x

2026-10-15S2

Wk 9 · Vol 0.67x

2026-10-14S2

Wk 9 · Vol 0.75x

2026-10-13S2

Wk 9 · Vol 0.57x

2026-10-12S2

Wk 8 · Vol 0.36x

2026-10-09S2

Wk 8 · Vol 0.97x

2026-10-08S2

Wk 8 · Vol 0.84x

2026-10-07S2

Wk 8 · Vol 0.42x

Moving averages & range

50 DMA

$4.63

200 DMA

$4.00

52W High

$5.34

52W Low

$2.04

5D Low

$4.06

Resistance levels (recent highs)

20d High

$4.75

60d High

$5.34

120d High

$5.34

250d High

$5.34

Next resistance

+15.3%

to 20d High

P/E (TTM)

1.0

Forward -51.5

Earnings Growth (YoY)

+493.5%

Revenue —

ROE

+74.2%

Profit margin 0.0%

Dividend Yield

6.04%

P/B 0.5

Oramed Pharmaceuticals: quick answers

What stage is Oramed Pharmaceuticals in?

As of Oct 22, 2026, Oramed Pharmaceuticals (ORMP) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 17, 2026 and is in week 10. What the four stages mean

Is Oramed Pharmaceuticals in an uptrend?

Yes. Oramed Pharmaceuticals is in a Stage 2 uptrend. It trades 2.9% above its 200-day average, which is rising.

How far is Oramed Pharmaceuticals from its 52-week high?

Oramed Pharmaceuticals closed at $4.12 on Oct 22, 2026, 22.8% below its 52-week high of $5.34. Its 52-week low is $2.04.

How has Oramed Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Oramed Pharmaceuticals is up 88.9% over the past year and up 51.9% so far in 2026.

Which sector and industry is Oramed Pharmaceuticals in?

Oramed Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.